steer study semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss STEER: Wegovy Significantly Reduces Heart

Investigate the drug manufacturers responsibility and failure to warn

For example, the SELECT trial clearly demonstrated that semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Marso et al., 2016a)

My arm was sore for a few days like any other vaccine, then fine

If approved by the U.S

And now I'm finally on the same, uh, on the same page

The weight loss results from clinical trials are unlike anything we have seen before